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Abstract
Introduction: Erythrocytes carry apolipoprotein B on their membrane, but the determining factors of erythrocyte-bound
apolipoprotein B (ery-apoB) are unknown. We aimed to explore the determinants of ery-apoB to gain more insight into
potential mechanisms.
Methods: Subjects with and without CVD were included (N = 398). Ery-apoB was measured on fresh whole blood samples
using flow cytometry. Subjects with ery-apoB levels #0.20 a.u. were considered deficient. Carotid intima media thickness
(CIMT) was determined as a measure of (subclinical) atherosclerosis.
Results: Mean ery-apoB value was 23.2% lower in subjects with increased CIMT (0.8060.09 mm, N= 140) compared to
subjects with a normal CIMT (0.5760.08 mm, N= 258) (P = 0.007, adjusted P,0.001). CIMT and ery-apoB were inversely
correlated (Spearman’s r: –0.116, P = 0.021). A total of 55 subjects (13.6%) were considered ery-apoB deficient, which was
associated with a medical history of CVD (OR: 1.86, 95% CI 1.04–3.33; adjusted OR: 1.55; 95% CI 0.85–2.82). Discontinuation
of statins in 54 subjects did not influence ery-apoB values despite a 58.4% increase in serum apolipoprotein B. Subjects with
blood group O had significantly higher ery-apoB values (1.5660.94 a.u.) when compared to subjects with blood group A
(0.8961.15 a.u), blood group B (0.7360.1.12 a.u.) or blood group AB (0.6960.69 a.u.) (P-ANOVA=0.002).
Conclusion: Absence or very low values of ery-apoB are associated with clinical and subclinical atherosclerosis. While serum
apolipoprotein B is not associated with ery-apoB, the ABO blood group seems to be a significant determinant.
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Introduction
The cardiovascular complications of atherosclerosis remain a
major health problem in the general population. Atherosclerosis is
a slowly progressive disease, induced by numerous risk factors
contributing to lipid deposition, inflammation and atherothrom-
bosis [1]. Apolipoprotein (apo) B is the structural protein of the
atherogenic lipoproteins including chylomicrons and their rem-
nants, VLDL, IDL and LDL. Large studies have shown that the
concentration of serum apo B is a strong predictor of CVD [2–4].
Lipoproteins are found in the fluid phase where they are
metabolized and transported to specific organs. However, there
is also evidence of a marginated pool of apo B containing
lipoproteins attached to the endothelium and to circulating blood
cells [5,6]. Close interaction exists between circulating leukocytes
and apo B containing lipoproteins as has been demonstrated in
human studies [7–9].
Erythrocytes represent the largest blood cell population and
make up more than 99% of the total cellular space in blood [10]. It
has been suggested that the exchange of cholesterolesters between
LDL and erythrocyte membranes may be substantial, which can
only be explained by binding of LDL to erythrocytes and not by
accidental collision [11,12]. Recently, it was shown that erythro-
cytes may contribute to reverse cholesterol transport with
impairment of reverse cholesterol transport in anemic mice [13].
In a relatively small pilot study, binding of apolipoprotein (apo) B
containing lipoproteins to erythrocytes (ery-apoB) was proposed as
a protective factor for cardiovascular disease (CVD) [14]. In this
study no clear correlation was observed between serum apo B
concentrations and ery-apoB and no significant determinants of
ery-apoB were detected.
We investigated the association of ery-apoB with carotid intima
media thickness (CIMT) and CVD in a larger study population. In
addition, we tested whether statins and serum apo B concentra-
tions influence ery-apoB values in a separate group of subjects.
Finally, we explored the association between the ABO blood
group system and ery-apoB values.
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Materials and Methods
Subjects
Participants were recruited from the outpatient clinics of the
Diabetes Vascular Center and the department of Cardiology, Sint
Franciscus Gasthuis in Rotterdam, for the measurement of ery-
apoB. The inclusion was carried out between July 2009 and
February 2013. Both subjects with and without a history of CVD
were included since we expected an atheroprotective effect from
ery-apoB. A history of CVD was defined as the presence of at least
one of the following conditions before inclusion: a myocardial
infarction, angina pectoris based on clinical characteristics,
documented coronary artery disease based on a coronary
angiogram, a cerebral infarction or the presence of peripheral
artery disease. Exclusion criteria were age ,18 years or the use of
any experimental medication within 6 months before participa-
tion. Anthropometric characteristics, e.g. weight, length, BMI,
waist circumference and blood pressure measurements were
recorded. Carotid ultrasound scans were carried out to measure
carotid intima media thickness (CIMT) using the ART-LAB
(Esaote, Italy), which has been described in detail previously [14].
ABO blood groups were obtained from the clinical registry
system and if not available, participants were asked to have their
ABO blood group determined in our hospital on a separate
occasion.
A separate group of subjects who used statins for primary
cardiovascular prevention discontinued their statin therapy to
investigate the effect of statins and subsequent changes in serum
apo B concentrations on ery-apoB values. Participants using
statins, but not other lipid lowering drugs, visited the outpatient
clinic for baseline measurements including ery-apoB and they
were asked to discontinue statin therapy for 6 weeks followed by a
second visit including a second blood draw with the measurement
of ery-apoB. The subjects were fasting during both visits. This
substudy was registered at Clinicaltrials.gov (NCT01634906).
All subjects provided written informed consent. The studies
were approved by the independent Regional Medical Ethical
Committee Rotterdam, Maasstad Hospital, the Netherlands.
In vivo measurement of ery-apoB
Blood samples for the determination apo B bound to
erythrocytes were obtained in tubes containing 5.4 mg K2 EDTA
(Becton Dickinson, Plymouth, UK). The staining procedure was
started within one hour after venipuncture. The method has been
described in detail previously [7,14]. To avoid interference of
serum lipoproteins, the samples were washed three times in PBS
supplemented with 0.5% BSA (PBS-BSA). The erythrocytes were
incubated with a polyclonal goat antibody directed against human
apo B (catalogue no. AB742; Millipore, Billerica, MA, USA) for 30
minutes in the dark on ice. Subsequently, the erythrocytes were
washed with PBS-BSA and incubated with a rabbit anti-goat
(RAG) antibody conjugated with FITC (Nordic Immunological
Laboratories, Tilburg, the Netherlands) for another 30 minutes in
the dark on ice. As a control for background staining, each sample
was simultaneously stained in parallel without anti-apo B
antibodies, but with RAG-FITC. Samples were kept in the dark
on ice until measurement. A total of 5000 erythrocytes per sample
were analysed by flow cytometry using an Epics XL-flow
cytometer (Beckman Coulter, Miami, Florida, USA). An FC500
flow cytometer (Beckman Coulter) was used in case of the statin
withdrawal sub-study. Before each use, the optics and settings of
the flow cytometer were checked with Flow-Check and Flow-Set
beads (Beckman Coulter). Identical flow cytometric settings were
used for the complete study.
Table 1. Characteristics of subjects based on carotid intima media thickness and on deficiency of ery-apoB (ery-apoB #0.20 a.u.)
and ery-apoB sufficiency (ery-apoB .0.20 a.u.).
CIMT ,0.70
(N=258)
CIMT $ 0.70
(N=140) P-value
Ery-apoB deficiency
(N=55)
Ery-apoB sufficiency
(N=343) P-value
Age (years) 54.2611.7 65.868.7 ,0.001 60.8613.3 58.0611.9 0.11
Male gender (n, %) 125 (48.4) 94 (67.1) ,0.001 31 (56.4) 187 (54.4) 0.78
History of T2DM (n, %) 31 (12.0) 35 (25.0) 0.001 13 (23.6) 58 (16.9) 0.22
History of CVD (n, %) 99 (38.4) 91 (65.0) ,0.001 33 (60.0) 153 (44.6) 0.03
Use of statins (n, %) 100 (43.4) 97 (69.3) ,0.001 35 (63.6) 173 (50.7) 0.08
BMI (kg/m2) 26.464.5 27.964.6 0.001 27.564.8 27.064.6 0.41
CIMT (mm) 0.5760.08 0.8060.09 ,0.001 0.67360.132 0.6466143 0.19
Hemoglobin (mmol/l) 8.860.7 8.860.9 0.72 8.860.86 8.860.7 0.89
Erythrocytes (*1012/l) 4.660.4 4.660.4 0.33 4.660.4 4.660.4 0.80
Leukocytes (*109/l) 6.561.9 6.961.7 0.04 7.261.6 6.561.8 0.02
Platelets (*109/l) 232654 237659 0.47 244658 232656 0.13
C-reactive protein (mg/l) 2.763.0 3.363.0 0.10 3.663.9 2.762.8 0.06
Total cholesterol (mmol/l) 4.961.2 4.761.1 0.12 4.761.1 4.961.2 0.35
LDL-C (mmol/l) 2.961.1 2.761.0 0.19 2.761.0 2.861.1 0.51
HDL-C (mmol/l) 1.4460.42 1.3160.38 0.01 1.2660.36 1.4160.42 0.01
Triglycerides (mmol/l) 1.4461.01 1.6860.93 0.03 1.7060.97 1.5060.99 0.16
Apolipoprotein B (g/l) 0.9360.29 0.9360.25 0.96 0.9260.26 0.9360.27 0.78
Apolipoprotein AI (g/l) 1.5660.32 1.5060.24 0.10 1.4860.25 1.5560.31 0.14
Abbreviations: BMI = body mass index; CIMT = carotid intima media thickness.
doi:10.1371/journal.pone.0075573.t001
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Laboratory measurements
All clinical and haematological chemistry measurements were
carried out on freshly drawn blood samples and analysed in the
Department of Clinical Chemistry, Sint Franciscus Gasthuis.
Baseline glucose, plasma cholesterol, HDL-C, triglycerides, C-
reactive protein, creatine kinase, ALAT and ASAT were measured
using the LX20 and DxC analyzers (Beckman Coulter). LDL-C
values were calculated using the Friedewald formula. Apo A-I and
apo B were determined by nephelometry using an IMMAGE
instrument with commercially available kits (Beckman Coulter).
Blood cell counts were determined automatically using LH750 and
DxH800 analyzers (Beckman Coulter). Thyroid function (TSH)
was determined by TSH measurement (Immulite 2500; Siemens,
Healthcare Diagnostics, Deerfield, Illinois, USA). The ABO blood
group was determined by standard procedures using agglutination
techniques (Galileo Echo; Immucor Gamma, Heppignies, Bel-
gium).
Statistics
The binding of apo B on erythrocytes was expressed as the
mean difference between fluorescence intensity of apo B-staining
and control background staining in arbitrary units (a.u.). The
mean fluorescence intensity reflects the amount of apo B per
erythrocyte. For statistical analysis, CIMT was defined as the
mean of the six individual measurements. Subjects were divided
into two groups: a normal CIMT (,0.70 mm) or increased CIMT
($0.70 mm). Linear regression analysis (backward stepwise) was
used to test the differential impact of ery-apoB on CIMT adjusted
for multiple variables. The variables included were age, gender, a
medical history of CVD, BMI, HDL-C, T2DM and the following
interaction effects: CIMT 6 gender, CIMT 6 CVD, CIMT 6
T2DM, CIMT6age, CIMT6BMI, CIMT6HDL-C, BMI6
HDL-C, BMI6T2DM, CVD6 age, T2DM6 age, T2DM6
HDL-C, HDL- 6 gender, CVD 6 HDL-C, CVD 6 BMI.
Subjects with ery-apoB levels ranging from undetectable to 0.20
a.u. were considered ery-apoB deficient. Since leukocyte count
and HDL-C were significantly different between ery-apoB
deficient and sufficient subjects, the impact of ery-apoB deficiency
on CVD risk was adjusted for leukocyte count and HDL-C using
multiple binary logistic regression analysis.
A power calculation demonstrated that at least 53 subjects were
necessary to demonstrate a significant difference of 0.2560.64 a.u.
in ery-apoB after statin withdrawal (power 80%, alpha 0.05 two-
sided). The subjects with ABO blood group measurements were
divided into tertiles based upon their ery-apoB values to test the
distribution of the ABO blood group between the respective
tertiles with the Chi-square test. Differences in continuous
variables between two groups were tested with the independent
Student’s t-test. One-way ANOVA with LSD as post-hoc analysis
was used for comparing multiple groups. The LSD test was not
corrected for multiple comparisons. However, we performed the
LSD test only when the overall ANOVA resulted in a P value less
than 0.05.
Skewed variables, which included ery-apoB, triglycerides and
C-reactive protein, were logarithmically transformed before
analysis, but non-transformed data are shown in the text and
tables. Correlations were obtained using the bivariate Spearman’s
correlation. All statistical analyses were performed using PASW
statistics version 18.0 (IBM SPSS Statistics, New York, United
States). A P-value of ,0.05 (two sided) was regarded as statistical
significant.
Results
Carotid intima media thickness and ery-apoB
A total of 409 subjects were included in the study. Levels of ery-
apoB were missing in 11 subjects due to technical failures and they
were left out of the analysis. A total of 258 subjects (64.8%) showed
a normal CIMT and 140 (35.2%) had an increased CIMT.
Baseline characteristics of these subjects are shown in Table 1.
Subjects with an increased CIMT were older and were more
frequently male and obese. They had more frequently a medical
history of CVD and used more often statins. The serum apo B
concentration was similar between the two groups. Ery-apoB was
significantly lower in subjects with increased CIMT (0.8960.83
a.u.) compared to subjects with a normal CIMT (1.1660.92;
P= 0.007). The difference between the two groups remained
significant after adjustment for multiple variables (0.7160.08 a.u.
versus 0.6060.14 a.u.; P,0.001). A reverse correlation existed
between CIMT and ery-apoB (Spearman’s r: 20.116, P = 0.021).
Ery-apoB deficiency and CVD risk
A total of 55 subjects (13.8%) were deficient for ery-apoB with
undetectable to very low (#0.20 a.u.) ery-apoB values. The
remaining subjects were classified as ery-apoB sufficient (N= 343).
Characteristics of the two groups are shown in Table 1. The two
groups were comparable, except for a higher leukocyte count and
lower HDL-C in the ery-apoB deficient group. The risk of CVD
was significantly higher in the ery-apoB deficient group compared
to the ery-apoB sufficient group (60.0% vs 44.6%, P= 0.034).
Ery-apoB deficiency was associated with an almost two-fold
increased prevalence of a medical history of CVD (OR 1.86; 95%
CI 1.04–3.33). However, after adjustment for HDL-C and
leukocytes the association did not reach statistical significance
(adjusted OR 1.55; 95% CI 0.85–2.82).
The effect of statin use on ery-apoB
The impact of statin withdrawal on serum apo B and ery-apoB
values were tested in a group of 54 subjects who discontinued their
Figure 1. Discontinuation of statin therapy did not affect
erythrocyte-bound apolipoprotein B (ery-apoB). Ery-apoB was
measured in subjects using statins (N = 54) at baseline and after
discontinuing statin therapy for 6 weeks. Individual ery-apoB levels
remained fairly stable during the 6 weeks of follow-up since ery-apoB at
baseline was strongly correlated to ery-apoB after discontinuing statin
therapy for 6 weeks (Spearman r: 0.828; P,0.001).
doi:10.1371/journal.pone.0075573.g001
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statin therapy for 6 weeks. As expected, total cholesterol, LDL-C,
triglycerides and serum apo B increased, whereas creatine kinase
and aspartate aminotransferase decreased 6 weeks after statin
withdrawal (Table S1). Ery-apoB remained unchanged before and
after discontinuation with a mean change in ery-apoB of -
0.0460.39 (P= 0.49) after statin withdrawal. Ery-apoB at baseline
was strongly correlated to ery-apoB after discontinuing statin
therapy for 6 weeks (Spearman r: 0.828; P,0.001) (Figure 1). Ery-
apoB did not correlate with serum apo B before (Spearman r:
20.025; P= 0.857) nor after 6 weeks of statin withdrawal
(Spearman r: 0.038; P= 0.786).
Relationship between ABO blood group and ery-apoB
The ABO blood group was included in the analyses to evaluate
factors related to ery-apoB. The ABO blood group was available
in only 104 subjects of the original cohort. Subjects were divided
into tertiles based on their ery-apoB value. The mean ery-apoB
value for each of the tertiles were 0.1760.11 a.u., 0.9860.36 a.u.
and 2.4660.76 a.u., respectively. The prevalence of CVD was
lowest in the third tertile (55.9%) when compared to the first
(82.3%) and second tertile (82.3%) with a similar trend for the use
of statins (Table S2). The prevalence of blood group A, B and AB
were markedly higher in the first tertile when compared to the
third tertile, whereas blood group O was much more prevalent in
the second and third tertile when compared to the first tertile
(P = 0.002) (Figure 2A).
Ery-apoB levels were also analyzed when subjects were divided
according to the ABO blood group phenotype. Subjects with
blood group A showed higher LDL-C concentrations when
compared to subjects with blood group O (Table 2). Mean ery-
apoB levels were 1.5660.94 a.u. in subjects with blood group O
(N=51), which was almost two-fold higher when compared to
subjects with blood group A (N=39) (0.8961.15 a.u.; P,0.001),
blood group B (N=6) (0.7361.12 a.u.; P = 0.02) or blood group
AB (N=8) (0.6960.69 a.u.; P = 0.015) (Figure 2B).
Figure 2. The association between erythrocyte-bound apolipoprotein B (ery-apoB) and ABO blood group phenotypes. The
prevalence of the ABO blood group phenotypes per tertile are shown (A). Tertiles are based upon ery-apoB. The first tertile represents the group with
the lowest ery-apoB, whereas the third tertile represents the subjects with the highest ery-apoB. The prevalence of ABO blood group phenotypes was
significantly different between the three groups (P = 0.002). Ery-apoB levels were almost two-fold increased in subjects with blood group O when
compared to subjects with blood group A, B or AB (P-ANOVA ,0.001) (B). *P,0.05 when compared to subjects with blood group A, B or AB.
doi:10.1371/journal.pone.0075573.g002
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Discussion
Our study confirmed the association of ery-apoB with clinical
and subclinical atherosclerosis in an extended study population
[14]. Ery-apoB was lower in subjects with increased CIMT and
very low to undetectable values of ery-apoB were associated with
an increased CVD risk. Recently, it was demonstrated in a mouse
model that erythrocytes contribute to reverse cholesterol transport,
particularly when the number of HDL particles is low [13].
Erythrocyte mediated reverse cholesterol transport by binding of
atherogenic apo B containing lipoproteins could potentially
explain the atheroprotective effect of ery-apoB suggested by the
present data. In addition, we hypothesize a protective mechanism
in which apo B containing lipoproteins bound to erythrocytes are
less likely to interact with the endothelium [6,14]. The observation
that anemia is associated with the development of CVD is also in
line with our hypothesis [15].
We did not observe any changes in ery-apoB in the group of
subjects who discontinued their statin therapy, despite a marked
increase in serum apo B. In our comparison between subjects with
normal and increased CIMT we did not correct for the use of
statins, although subjects with increased CIMT used statins more
frequently. In the present study we clearly demonstrated that
statins do not influence ery-apoB since there was no change after
discontinuation. In addition, there was no association between
serum apo B and ery-apoB [14]. We have chosen to study the
effects of statin withdrawal for a period of 6 weeks on ery-apoB,
because serum concentrations of apo B and LDL-C return to
baseline within 4 weeks. In addition, the lifespan of erythrocytes is
approximately 12 weeks and half of all erythrocytes would have
been renewed within 6 weeks, which potentially may have shown
changes in the renewed erythrocyte population. We hypothesize
that the adherence of apo B containing lipoproteins to erythrocytes
is dynamic with a continuous process of adherence and release of
lipoproteins. Therefore, we presume that a period of 6 weeks of
statin withdrawal would have been sufficient to study the effects of
statins and changes in serum apo B on ery-apoB. Furthermore, we
do not think that it would be ethical for patients to refrain from a
necessary treatment for a longer period of time.
The exact binding mechanism of apo B containing lipoproteins
to erythrocytes has not yet been elucidated. The LDL receptor
seems to be a logical candidate to bind apo B containing
lipoproteins to erythrocytes but it is not expressed on erythrocytes
[11,12]. Therefore, other binding mechanisms must be operation-
al. The exchange of cholesterolesters between LDL and erythro-
cyte membranes may be substantial and could not be explained by
accidental collision [11,12]. Here we show for the first time that
the ABO blood group system may influence the binding of apo B
containing lipoproteins to erythrocytes. Interestingly, we found
that ery-apoB levels were almost two-fold increased in subjects
with blood group O when compared to subjects with blood group
A, B or AB. We have to admit that the ABO blood group was only
available in 104 of the total 409 subjects and that the number of
subjects with blood group B and AB was low. This could have
resulted in a selection bias. However, the results were so striking,
that we decided to include them in the current paper. Studies are
underway in our laboratory to gain more insight in the
relationship between blood groups and ery-apoB. It is tempting
to speculate that different carbohydrate groups on the apo B
molecule interact with fucose, galactose, N acetyl-galactosamine or
N acetyle-glucosamine, which make up the A, B and H antigens
[16].
Table 2. Characteristics of a select group of subjects with measurements of erythrocyte-bound apolipoprotein B (ery-apoB) and
ABO blood group phenotype.
A (N=39) B (N=6) AB(N=8) O (N=51) P-value
Age (years) 61.769.5 56.7616.7 67.668.6 61.769.3 0.23
Male gender (n, %) 24 (61.5) 3 (50.0) 5 (62.5) 31 (60.8) 0.96
History of T2DM (n, %) 9 (23.1) 0 (0.0) 3 (37.5) 10 (19.6) 0.38
History of CVD (n, %) 27 (69.2) 4 (66.7) 7 (87.5) 39 (76.5) 0.67
Use of statins (n, %) 27 (69.2) 5 (83.3) 8 (100.0) 41 (80.3) 0.30
BMI (kg/m2) 27.065.2 28.364.2 27.963.8 27.165.0 0.92
Hemoglobin (mmol/l) 8.860.8 8.960.6 8.561.1 8.960.8 0.72
Erythrocytes (*1012/l) 4.660.4 4.760.4 4.460.6 4.660.4 0.53
Leukocytes (*109/l) 7.161.6 6.161.2 6.861.0 6.561.6 0.22
Platelets (*109/l) 235656 237648 252663 226645 0.55
C-reactive protein (mg/l) 3.463.9 1.861.0 2.762.5 2.261.8 0.34
Ery-apoB (a.u.) 0.8961.15* 0.7361.12* 0.6960.69* 1.5660.94*** ,0.001
Total cholesterol (mmol/l) 4.761.0 4.461.3 4.160.8 4.460.9 0.18
LDL-C (mmol/l) 2.760.9* 1.961.0 2.360.6 2.260.8** 0.04
HDL-C (mmol/l) 1.3460.37 1.6360.65 1.3060.41 1.4260.46 0.41
Triglycerides (mmol/l) 1.6560.85 1.8861.83 1.0960.60 1.7661.11 0.36
Apolipoprotein B (g/l) 0.9160.24 0.7560.24 0.8060.18 0.8260.19 0.12
Apolipoprotein AI (g/l) 1.5760.29 1.5760.27 1.5260.30 1.6060.35 0.90
Subjects were divided according to ABO blood group phenotype.
*Significantly different when compared to blood group O (P,0.05).
**Significantly different when compared to blood group A (P,0.05).
***Significantly different when compared to blood group A, B or AB (all P,0.05).
doi:10.1371/journal.pone.0075573.t002
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The ABO blood group system has already been associated with
plasma cholesterol concentrations more than 40 years ago [17,18].
Blood group O has been associated with slightly lower cholesterol
levels [19], whereas others have found associations between blood
group A and elevated plasma concentrations for total cholesterol
[20,21], and LDL-C [21]. We found similar results in our study
with elevated plasma LDL-C levels in subjects with blood group A.
Besides with lipids, the ABO blood group system has been
associated with CVD. Factors involved in this association are
potentially Factor VIII, Von Willebrand Factor, endothelial
molecules and platelet proteins [22,23]. Recently, two large
prospective cohort studies plus a meta-analysis demonstrated that
the non-O blood group has a higher risk of CVD (RR 1.11;
95%CI 1.05 – 1.18) and that 6.27% of the CVD cases were
attributable to inheriting the non-O blood group [24]. Our finding
that ery-apoB is associated with both an atheroprotective effect
similar to blood group O is in line with these observations.
Prospective data regarding ery-apoB and incident CVD are still
lacking and the clinical value of ery-apoB as a biomarker in
cardiovascular risk prediction needs to be determined.
In conclusion, absence or very low ery-apoB is associated with
the presence of clinical and subclinical atherosclerosis. The
evaluation of ery-apoB as a clinical useful risk factor for CVD
needs to be determined in a large prospective study. Blood group
O was strongly associated with high ery-apoB and may provide a
new explanation for the association between the ABO blood group
system and CVD and plasma lipids. Statins and serum apo B do
not affect ery-apoB.
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